drugset / Trial / NCT05465798

Beta-glucans for Hospitalised Patients With COVID-19

NCT05465798 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.

Timeline

Start
2023-06
Primary completion
2024-10
Completion
2024-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 1,3 beta-Glucans Other / unclassified 25 mg Oral

Indications